References
- ALSUntangled [online]. Available at: https://www.alsuntangled.com/future-reviews/. Accessed March 4, 2021.
- Ferlazzo N, Andolina G, Cannata A, Costanzo M, Rizzo V, Curro M, et al. Is melatonin the cornucopia of the 21st century? Antioxidants. 2020;9:1088.
- Jacob S, Poeggeler B, Weishaupt J, Sire’n A, Hardeland R, Ba’hr M. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 2002;33:186–7.
- Srinivasan V, Pandi-Perumal S, Maestroni G, Esquifino A, Hardeland R, Cardinali D. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005;7:293–318.
- Luo F, Sandhu A, Rungratanawanich W, Williams G, Akbar M, Zhou S, et al. Melatonin and autophagy in aging-related neurodegenerative diseases. Int J Mol Sci. 2020;21:7174.
- Acupuncture Today [online]. Available at: https://www.acupuncturetoday.com/mpacms/at/article.php?id=33066. Accessed March 11, 2021.
- Simpson E, Henry Y, Henkel J, Smith R, Appel S. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004;62:1758–65.
- Smith G, Henry Y, Mattson M, Appel S. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 1998;44:696–9.
- Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep 2019;29:1164–77.
- Johns J. Estimation of melatonin blood brain barrier permeability. J Bioanal Biomed 2011;3:64–9.
- Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res. 2004;36:25–32.
- Permpoonputtana K, Tangweerasing P, Mukda S, Boontem P, Nopparat C, Govitrapong P. Long-term administration of melatonin attenuates neuroinflammation in the aged mouse brain. Excli J 2018;17:634–46.
- Yang Z, Bao Y, Chen W, He Y. Melatonin exerts neuroprotective effects by attenuating astro- and microgliosis and suppressing inflammatory response following spinal cord injury. Neuropeptides 2020;79:102002.
- Yosefifard M, Vaezi G, Malekirad A, Faraji F, Hojati V. A randomized control trial study to determine the effect of melatonin on serum levels of IL-1B and TNF-a in patients with multiple sclerosis. 2019;18:649–54.
- Sanchez-Lopez A, Ortiz G, Pacheco-Moises F, Mireles-Ramirez M, Bitzer-Quintero O, Delgado-Lara D, et al. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch Med Res. 2018;49:391–8.
- Weishaupt J, Bartels C, Polking E, Dietrich J, Rhode G, Poeggeler B, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41:313–23.
- Jaiswal MK. Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediatedexcitotoxicity induced disrupted mitochondrial Ca2 signaling in amyotrophic lateral sclerosis. Front Cell Neurosci 2017;10:1–14.
- Dardiotis E, Panayiotou E, Feldman ML, Hadjisavvas A, Malas S, Vonta I, et al. Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci Lett 2013;548:170–5.
- Zhang Y, Cook A, Kim J, Baranov S, Jiang J, Smith K, et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss, and delays progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2013;55:26–35.
- PatientsLikeMe [online]. Available at: https://www.patientslikeme.com/treatment_evaluations/browse?brand=false&condition_id=9&id=51 Accessed March 21, 2021.
- ALS Reversals [online]. Available at: http://www.alsreversals.com. Accessed March 24, 2021.
- Harrison D, Mehta P, Van Es M, Stommel E, Drory V, Nefussy B, et al. “ALS reversals:” demographics, disease characteristics, treatments and co-morbidities. Amyotrophic Lateral Scler Frontotemporal Degen 2018;19:495–9.
- Bald E, Nance C, Schultz J. Melatonin may slow disease progression in amyotrophic lateral sclerosis: findings from the pooled resource open-access clinical trials database. Muscle Nerve. 2021;63:572– 5.
- Besag F, Vasey M, Lao K, Wong I. Adverse events associated with melatonin for the treatment of primary or secondary sleep disorders: a systematic review. CNS Drugs.2019;33:1167–86.
- Andersen L, Gogenur I, Rosenberg J, Reiter R. The safety of melatonin in humans. Clin Drug Invest 2016;36:169–75.
- Good RX [online]. Available at: https://www.goodrx.com/melatonin. Accessed March 26, 2021.